Real-world evidence (RWE) has long promised to bridge the chasm between what works in trials and what happens in practice. Yet over the past few years, it has done something bolder; it has crossed into the realm of comparative evidence. The “real-world comparator,” which used to be dismissed as an oddity of rare disease research has quietly become one of the most contested frontiers in evidence generation.  This topic was discussed during the recent Adigens Health webinar f

RWE requires transparency. Target trial emulation offers it and now there is an explicit statement on how to report the findings.

A summary of the new position paper on the use of RWE by FDA authors

The European Medicines Agency (EMA) just released its third annual report on real-world evidence (RWE) in regulatory decision-making and...